Global Biosimilars of Rituximab Market Research Report 2021

1 Biosimilars of Rituximab Market Overview

• 1.1 Product Overview and Scope of Biosimilars of Rituximab
• 1.2 Biosimilars of Rituximab Segment by Type
  • 1.2.1 Global Biosimilars of Rituximab Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 500mg
  • 1.2.3 100mg
  • 1.2.4 Other
• 1.3 Biosimilars of Rituximab Segment by Application
  • 1.3.1 Global Biosimilars of Rituximab Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
• 1.4 Global Biosimilars of Rituximab Market Size Estimates and Forecasts
  • 1.4.1 Global Biosimilars of Rituximab Revenue 2016-2027
  • 1.4.2 Global Biosimilars of Rituximab Sales 2016-2027
  • 1.4.3 Biosimilars of Rituximab Market Size by Region: 2016 Versus 2021 Versus 2027

2 Biosimilars of Rituximab Market Competition by Manufacturers

• 2.1 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Biosimilars of Rituximab Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Biosimilars of Rituximab Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Biosimilars of Rituximab Manufacturing Sites, Area Served, Product Type
• 2.5 Biosimilars of Rituximab Market Competitive Situation and Trends
  • 2.5.1 Biosimilars of Rituximab Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Biosimilars of Rituximab Players Market Share by Revenue
  • 2.5.3 Global Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Biosimilars of Rituximab Retrospective Market Scenario by Region

• 3.1 Global Biosimilars of Rituximab Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.2 Global Biosimilars of Rituximab Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.3 North America Biosimilars of Rituximab Market Facts & Figures by Country
  • 3.3.1 North America Biosimilars of Rituximab Sales by Country
  • 3.3.2 North America Biosimilars of Rituximab Revenue by Country
  • 3.3.3 United States
  • 3.3.4 Canada
• 3.4 Europe Biosimilars of Rituximab Market Facts & Figures by Country
  • 3.4.1 Europe Biosimilars of Rituximab Sales by Country
  • 3.4.2 Europe Biosimilars of Rituximab Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Biosimilars of Rituximab Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Biosimilars of Rituximab Sales by Region
  • 3.5.2 Asia Pacific Biosimilars of Rituximab Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
• 3.6 Latin America Biosimilars of Rituximab Market Facts & Figures by Country
  • 3.6.1 Latin America Biosimilars of Rituximab Sales by Country
  • 3.6.2 Latin America Biosimilars of Rituximab Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Biosimilars of Rituximab Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Biosimilars of Rituximab Sales by Country
  • 3.7.2 Middle East and Africa Biosimilars of Rituximab Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Biosimilars of Rituximab Historic Market Analysis by Type

• 4.1 Global Biosimilars of Rituximab Sales Market Share by Type (2016-2021)
• 4.2 Global Biosimilars of Rituximab Revenue Market Share by Type (2016-2021)
• 4.3 Global Biosimilars of Rituximab Price by Type (2016-2021)

5 Global Biosimilars of Rituximab Historic Market Analysis by Application

• 5.1 Global Biosimilars of Rituximab Sales Market Share by Application (2016-2021)
• 5.2 Global Biosimilars of Rituximab Revenue Market Share by Application (2016-2021)
• 5.3 Global Biosimilars of Rituximab Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Amgen
  • 6.1.1 Amgen Corporation Information
  • 6.1.2 Amgen Description and Business Overview
  • 6.1.3 Amgen Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Amgen Biosimilars of Rituximab Product Portfolio
  • 6.1.5 Amgen Recent Developments/Updates
• 6.2 AryoGen Pharmed
  • 6.2.1 AryoGen Pharmed Corporation Information
  • 6.2.2 AryoGen Pharmed Description and Business Overview
  • 6.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 AryoGen Pharmed Biosimilars of Rituximab Product Portfolio
  • 6.2.5 AryoGen Pharmed Recent Developments/Updates
• 6.3 Biocad
  • 6.3.1 Biocad Corporation Information
  • 6.3.2 Biocad Description and Business Overview
  • 6.3.3 Biocad Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Biocad Biosimilars of Rituximab Product Portfolio
  • 6.3.5 Biocad Recent Developments/Updates
• 6.4 Cadila Pharmaceuticals
  • 6.4.1 Cadila Pharmaceuticals Corporation Information
  • 6.4.2 Cadila Pharmaceuticals Description and Business Overview
  • 6.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio
  • 6.4.5 Cadila Pharmaceuticals Recent Developments/Updates
• 6.5 Celltrion
  • 6.5.1 Celltrion Corporation Information
  • 6.5.2 Celltrion Description and Business Overview
  • 6.5.3 Celltrion Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Celltrion Biosimilars of Rituximab Product Portfolio
  • 6.5.5 Celltrion Recent Developments/Updates
• 6.6 Dr Reddy’s Laboratories
  • 6.6.1 Dr Reddy’s Laboratories Corporation Information
  • 6.6.2 Dr Reddy’s Laboratories Description and Business Overview
  • 6.6.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio
  • 6.6.5 Dr Reddy’s Laboratories Recent Developments/Updates
• 6.7 Teva
  • 6.6.1 Teva Corporation Information
  • 6.6.2 Teva Description and Business Overview
  • 6.6.3 Teva Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Teva Biosimilars of Rituximab Product Portfolio
  • 6.7.5 Teva Recent Developments/Updates
• 6.8 Hetero Group
  • 6.8.1 Hetero Group Corporation Information
  • 6.8.2 Hetero Group Description and Business Overview
  • 6.8.3 Hetero Group Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Hetero Group Biosimilars of Rituximab Product Portfolio
  • 6.8.5 Hetero Group Recent Developments/Updates
• 6.9 Innovent Biologics
  • 6.9.1 Innovent Biologics Corporation Information
  • 6.9.2 Innovent Biologics Description and Business Overview
  • 6.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Innovent Biologics Biosimilars of Rituximab Product Portfolio
  • 6.9.5 Innovent Biologics Recent Developments/Updates
• 6.10 Intas Biopharmaceuticals
  • 6.10.1 Intas Biopharmaceuticals Corporation Information
  • 6.10.2 Intas Biopharmaceuticals Description and Business Overview
  • 6.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio
  • 6.10.5 Intas Biopharmaceuticals Recent Developments/Updates
• 6.11 Mylan
  • 6.11.1 Mylan Corporation Information
  • 6.11.2 Mylan Biosimilars of Rituximab Description and Business Overview
  • 6.11.3 Mylan Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Mylan Biosimilars of Rituximab Product Portfolio
  • 6.11.5 Mylan Recent Developments/Updates
• 6.12 Probiomed
  • 6.12.1 Probiomed Corporation Information
  • 6.12.2 Probiomed Biosimilars of Rituximab Description and Business Overview
  • 6.12.3 Probiomed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Probiomed Biosimilars of Rituximab Product Portfolio
  • 6.12.5 Probiomed Recent Developments/Updates
• 6.13 TRPharma
  • 6.13.1 TRPharma Corporation Information
  • 6.13.2 TRPharma Biosimilars of Rituximab Description and Business Overview
  • 6.13.3 TRPharma Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.13.4 TRPharma Biosimilars of Rituximab Product Portfolio
  • 6.13.5 TRPharma Recent Developments/Updates
• 6.14 Zenotech Laboratories
  • 6.14.1 Zenotech Laboratories Corporation Information
  • 6.14.2 Zenotech Laboratories Biosimilars of Rituximab Description and Business Overview
  • 6.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
  • 6.14.4 Zenotech Laboratories Biosimilars of Rituximab Product Portfolio
  • 6.14.5 Zenotech Laboratories Recent Developments/Updates

7 Biosimilars of Rituximab Manufacturing Cost Analysis

• 7.1 Biosimilars of Rituximab Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Biosimilars of Rituximab
• 7.4 Biosimilars of Rituximab Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Biosimilars of Rituximab Distributors List
• 8.3 Biosimilars of Rituximab Customers

9 Biosimilars of Rituximab Market Dynamics

• 9.1 Biosimilars of Rituximab Industry Trends
• 9.2 Biosimilars of Rituximab Growth Drivers
• 9.3 Biosimilars of Rituximab Market Challenges
• 9.4 Biosimilars of Rituximab Market Restraints

10 Global Market Forecast

• 10.1 Biosimilars of Rituximab Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Biosimilars of Rituximab by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Biosimilars of Rituximab by Type (2022-2027)
• 10.2 Biosimilars of Rituximab Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Biosimilars of Rituximab by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Biosimilars of Rituximab by Application (2022-2027)
• 10.3 Biosimilars of Rituximab Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Biosimilars of Rituximab by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Biosimilars of Rituximab by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List